These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 27669286)

  • 1. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
    Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
    Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function.
    Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA
    J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of K103N and/or Y181C HIV-1 mutations by exposure to zidovudine and non-nucleoside reverse transcriptase inhibitors.
    Torti C; Pozniak A; Nelson M; Hertogs K; Gazzard BG
    J Antimicrob Chemother; 2001 Jul; 48(1):113-6. PubMed ID: 11418520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
    Menéndez-Arias L; Betancor G; Matamoros T
    Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.
    Zhang XM; Wu H; Zhang Q; Lau TC; Chu H; Chen ZW; Jin DY; Zheng BJ
    J Antimicrob Chemother; 2015 May; 70(5):1381-90. PubMed ID: 25637519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strains.
    Huang Y; Li Z; Xing H; Jiao Y; Ouyang Y; Liao L; Jiang S; Armstrong R; Shao Y; Ma L
    PLoS One; 2014; 9(4):e93804. PubMed ID: 24743727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.
    Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V
    ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Barnard JP; Huber KD; Sluis-Cremer N
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31160281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1].
    Cao YL; Li SX; Chen H; Guo Y
    Yao Xue Xue Bao; 2009 Apr; 44(4):355-61. PubMed ID: 19545051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
    Xu HT; Colby-Germinario SP; Oliveira M; Rajotte D; Bethell R; Wainberg MA
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4515-26. PubMed ID: 24867966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.
    Ceccherini-Silberstein F; Svicher V; Sing T; Artese A; Santoro MM; Forbici F; Bertoli A; Alcaro S; Palamara G; d'Arminio Monforte A; Balzarini J; Antinori A; Lengauer T; Perno CF
    J Virol; 2007 Oct; 81(20):11507-19. PubMed ID: 17686836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
    Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
    Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions.
    Wang J; Bambara RA; Demeter LM; Dykes C
    J Virol; 2010 Sep; 84(18):9377-89. PubMed ID: 20592075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
    Reuman EC; Rhee SY; Holmes SP; Shafer RW
    J Antimicrob Chemother; 2010 Jul; 65(7):1477-85. PubMed ID: 20462946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients.
    Clevenbergh P; Cua E; Dam E; Durant J; Schmit JC; Boulme R; Cottalorda J; Beyou A; Schapiro JM; Clavel F; Dellamonica P
    HIV Clin Trials; 2002; 3(1):36-44. PubMed ID: 11819184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
    Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
    J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.